Import from '@/components/mdx'

CJC-1295 Legal & Regulatory Status: What Women Need to Know Before Using It

Why CJC-1295 Has No FDA Label

CJC-1295 has never been submitted for, let alone granted, FDA approval. There is no package insert, no approved dose, and no recognized therapeutic indication in the United States. The peptide exists in a legal corridor created by compounding pharmacy law, not by a drug-approval pathway.

What "Modified GRF 1-29" Actually Is

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The original GHRH fragment GRF 1-29 degrades rapidly in plasma. CJC-1295 adds a drug-affinity complex (DAC) or, in its DAC-free form, four amino-acid substitutions that extend its half-life from roughly two minutes to several days. The extended half-life is what makes it attractive for weekly subcutaneous dosing, but it also means the body's GH axis is stimulated far longer than any physiological pulse.

The Compounding-Pharmacy Pathway

Under 21 U.S.C. § 503A, a licensed pharmacist may compound a drug from bulk ingredients for an individually identified patient if a valid prescription exists and the drug is not on the FDA's "Demonstrably Difficult to Compound" list. CJC-1295 has never been on the FDA's officially nominated bulk-drug-substances list for 503A compounding, which means its legal status as a compounded product is contested. The FDA's bulk drug substances list does not include CJC-1295 as a nominated or evaluated substance, placing compounders who use it in direct regulatory jeopardy.

503B outsourcing facilities face an even stricter standard. They may only compound drugs from bulk substances that appear on the FDA's 503B bulks list, and CJC-1295 does not appear there either.

What the Only Major Clinical Trial Actually Found

The single most-cited human pharmacokinetic study of CJC-1295 is Teichman et al., published in the Journal of Clinical Endocrinology and Metabolism in 2006. Read it carefully before accepting anyone's dosing claims.

The Teichman 2006 Study: Design and Findings

The study enrolled 65 healthy adults and administered single or multiple subcutaneous doses of CJC-1295 DAC ranging from 30 to 120 mcg/kg. Mean GH concentrations increased two- to tenfold over baseline, and IGF-1 levels rose by 28 to 97 percent above baseline, remaining elevated for six to eight days after a single injection. The authors concluded that CJC-1295 produced "sustained, physiologically relevant increases in GH and IGF-1" Teichman et al., 2006.

The Women Problem in That Data

The Teichman cohort skewed heavily male. Sex-disaggregated pharmacokinetic data were not reported separately for female participants. Women naturally have higher basal GH pulse amplitude and frequency than age-matched men, a difference that widens during the reproductive years and narrows after menopause. Applying doses derived from a predominantly male dataset to women is a direct extrapolation, not an evidence-based practice. This is the evidence gap that every clinician prescribing this peptide to women should acknowledge plainly.

No Phase III Trial Has Ever Been Completed

The developer, ConjuChem Biotechnologies, pursued CJC-1295 as a potential treatment for adult growth-hormone deficiency but discontinued development before any Phase III trial. There is no completed randomized controlled trial in women, no dose-finding study stratified by menopausal status, and no long-term safety study in any sex. Every dosing regimen circulating online or in compounding pharmacy literature is extrapolated from that single Phase I/II study or from preclinical animal data.

FDA Enforcement Actions Against CJC-1295

The FDA has not ignored this peptide. Its enforcement activity tells you more about the legal reality than any compounding pharmacy's website.

Warning Letters and Import Alerts

Between 2018 and 2024, the FDA issued warning letters to multiple compounding pharmacies and online retailers marketing CJC-1295, typically citing:

• Sale of an unapproved new drug in violation of 21 U.S.C. § 355(a)
• Misbranding under 21 U.S.C. § 352 because the product lacks an approved label
• Adulteration concerns because bulk CJC-1295 powder sourced from foreign API manufacturers may not meet USP standards

The FDA's MedWatch adverse event system has received reports linked to compounded peptide products, although attribution to a specific compound is complicated by the polypharmacy common in peptide users.

Import Restrictions

CJC-1295 in bulk powder form is subject to FDA import alerts, which allow FDA field staff to detain shipments without physical examination when a pattern of violations exists. Companies marketing raw CJC-1295 powder directly to consumers as a "research chemical" operate outside both the drug-approval system and the compounding-pharmacy framework entirely.

State Board of Pharmacy Overlap

Even when the FDA does not act, state pharmacy boards can and do. Several states have issued cease-and-desist orders against pharmacies compounding CJC-1295 without patient-specific prescriptions or from unverified bulk sources. If you receive a compounded peptide and your pharmacist cannot show you a certificate of analysis from a third-party laboratory, you have no assurance of purity, potency, or sterility.

Sex-Specific Physiology: Why This Matters Differently for Women

Endogenous growth hormone secretion is not the same in women as in men. The GH-IGF-1 axis varies by sex in ways that directly affect how a drug like CJC-1295 might behave in your body.

Reproductive Years

During the reproductive years, estrogen amplifies GH secretion by reducing hepatic IGF-1 sensitivity, which means the pituitary secretes more GH to maintain IGF-1 in the normal range. If you add a GHRH analogue on top of an already estrogen-primed GH axis, the net IGF-1 increase could be greater than what the Teichman data would predict. High IGF-1 is associated with cell-proliferative effects, and long-term elevations have been studied in relation to breast cancer risk, though causality from pharmacologic IGF-1 elevation in women over months or years has not been resolved.

PCOS

Women with polycystic ovary syndrome frequently have altered GH pulsatility and elevated baseline IGF-1 compared to non-PCOS controls. Stimulating the GH axis further in a woman who already has PCOS-related IGF-1 dysregulation has no studied safety profile. Any clinician offering CJC-1295 to a woman with PCOS as a weight-management or body-composition tool is doing so without supporting data specific to that population.

Perimenopause and Menopause

GH secretion declines with age in both sexes. The drop in estrogen at menopause accelerates this decline. Some longevity-medicine practitioners argue that GHRH stimulation could offset age-related GH decline in postmenopausal women, but no randomized trial has tested this hypothesis in women using CJC-1295 specifically. The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults notes that GH replacement in diagnosed deficiency requires lower starting doses in women taking oral estrogen because oral estrogen suppresses hepatic IGF-1 production and may require dose titration upward, a complexity absent from any compounding dosing guide.

Thyroid Disease

Women are five to eight times more likely than men to develop autoimmune thyroid disease. GH directly modulates thyroid hormone metabolism by increasing conversion of T4 to T3 and can unmask subclinical hypothyroidism. If you have Hashimoto thyroiditis or are on levothyroxine, adding a GHRH analogue without thyroid-function monitoring could shift your thyroid levels in ways your prescriber did not anticipate.

Pregnancy and Lactation: A Required Safety Review

CJC-1295 should not be used during pregnancy or while breastfeeding. This is not a soft caution. It reflects the complete absence of human safety data combined with known biological plausibility for fetal harm.

Pregnancy

CJC-1295 carries no FDA pregnancy category because it has never been approved. There are no published human pregnancy outcomes data. In preclinical terms, stimulating the maternal GH-IGF-1 axis during pregnancy raises theoretical concerns about fetal growth dysregulation, because IGF-1 is a primary driver of fetal and placental growth. Fetal IGF-1 concentrations are tightly regulated, and pharmacologic manipulation of the maternal axis could alter fetal IGF-1 exposure in unpredictable directions.

If you are trying to conceive, you should stop CJC-1295 before attempting pregnancy. Because the DAC version produces IGF-1 elevations lasting up to eight days per injection, a washout period of at least two to four weeks is a reasonable minimum, though no studied washout exists.

If you discover you are pregnant while using CJC-1295, stop immediately and inform your obstetric provider. Do not attempt to self-manage this disclosure.

Lactation

No lactation studies of CJC-1295 exist in humans or in any published animal model. The molecular weight of CJC-1295 (approximately 3,367 daltons) is large enough that passive diffusion into breast milk may be limited, but active transport cannot be excluded. Because GH and IGF-1 are normally present in breast milk and have roles in neonatal gut development, additional pharmacologic stimulation of this axis in a nursing mother is an unknown risk. Given zero evidence of safety and a plausible biological pathway to infant exposure, breastfeeding while using CJC-1295 is not recommended.

Contraception Requirement

No formal teratogenicity study has classified CJC-1295, but the preclinical concerns above mean that reliable contraception is strongly advisable for any woman of reproductive age using this peptide. If you are using hormonal contraception, be aware that oral estrogen-containing pills may blunt the IGF-1 response to GH stimulation (as described in the Endocrine Society GH guideline above), meaning your IGF-1 monitoring may underestimate the GH effect.

Who This Is Right For and Who Should Not Use It

No approved indication for CJC-1295 exists in any population. The following is a practical, evidence-based framework for women navigating this question with their clinician.

Women Who Face the Most Uncertainty

• Reproductive-age women not using reliable contraception. The pregnancy risk alone warrants extreme caution.
• Women with PCOS. Altered baseline IGF-1 and GH pulsatility make the expected response unpredictable.
• Women with active or past hormone-receptor-positive breast cancer. Any agent that elevates IGF-1 chronically requires oncology input.
• Women on thyroid replacement therapy. GH-axis stimulation can shift thyroid hormone metabolism and destabilize previously controlled hypothyroidism.
• Women with acromegaly history or pituitary adenoma. Stimulating a pituitary already prone to excess GH output is contraindicated.
• Pregnant or breastfeeding women. No use under any circumstance without documented safety data, which does not currently exist.

Women Who Might Discuss This With a Specialist

• Postmenopausal women with documented adult growth hormone deficiency confirmed by stimulation testing and managed by an endocrinologist. Even in this narrow group, approved GHRH analogues (such as tesamorelin, which is FDA-approved for HIV-associated lipodystrophy) exist and have a defined label.
• Women with age-related sarcopenia being managed in an academic research context under an Institutional Review Board protocol.

The honest answer for most women is that the risk-benefit calculation cannot be completed because the benefit side of the equation lacks women-specific data and the risk side lacks long-term safety data in any population.

Patent History and Commercial Development

CJC-1295 was developed by ConjuChem Biotechnologies, a Canadian peptide company, under patents covering the DAC modification technology. ConjuChem's CJC-1295 program advanced through Phase II clinical trials for adult GH deficiency before the company discontinued development in 2008. The original patents have either expired or lapsed, which is one reason bulk CJC-1295 powder is now available from Asian API manufacturers and enters the United States as a "research chemical."

The expired patent status does not confer legality. A drug can be off-patent and still be an unapproved new drug under the Food, Drug, and Cosmetic Act. The FDA's authority to regulate a substance as a drug is based on intended use, not on patent status.

The "Research Chemical" Loophole

Vendors who sell CJC-1295 powder labeled "For Research Use Only, Not for Human Consumption" are attempting to avoid FDA jurisdiction. The FDA has published guidance making clear that labeling a substance for research does not exempt it from drug-approval requirements if the intended use is human administration. Purchasing CJC-1295 from these vendors and self-injecting it places you entirely outside any regulatory safety net: no sterility testing, no potency verification, no adverse-event reporting system.

Safety Signals and Adverse Events

Because CJC-1295 has never completed a Phase III trial and is not approved, post-market surveillance in the formal sense does not exist. What does exist is a mix of case series, forum reports, and adverse events attributed to compounded peptides generally.

Known Short-Term Side Effects From Teichman 2006

The Phase I/II trial reported flushing, injection-site reactions, and headache as the most common adverse events at doses of 30 to 60 mcg/kg. One subject at the highest dose experienced transient hypotension. No serious adverse events were recorded, but the trial lasted only weeks in a healthy, young, predominantly male cohort.

Theoretical Long-Term Risks Specific to Women

• IGF-1 and breast tissue. The American Society of Clinical Oncology has flagged elevated IGF-1 as a potential breast cancer risk factor in observational data, though causality from pharmacologic IGF-1 elevation has not been established in controlled studies.
• Insulin resistance. Supraphysiologic GH impairs insulin sensitivity. Women with PCOS, prediabetes, or gestational diabetes history are at higher baseline risk.
• Fluid retention and carpal tunnel. These are well-recognized effects of pharmacologic GH excess, documented in studies of approved GH therapy, and would be expected with CJC-1295 at supraphysiologic doses.
• Pituitary feedback suppression. Chronic GHRH stimulation could theoretically desensitize pituitary somatotrophs, though the extent of this in humans using compounded CJC-1295 over months or years is unknown.

How to Protect Yourself If You Choose to Proceed

If, after reviewing all of the above with your own physician or endocrinologist, you decide to use compounded CJC-1295, these are the minimum safety steps that a clinician at WomanRx would expect to see in place.

1. Get a baseline IGF-1 level before starting. Without a baseline, you cannot monitor for supraphysiologic elevation.
2. Request a certificate of analysis from the compounding pharmacy for every batch, confirming identity, potency within 90 to 110 percent of labeled dose, and sterility.
3. Monitor IGF-1 at four to six weeks and adjust or stop if levels exceed the upper quartile of the age-appropriate reference range.
4. Check fasting glucose and insulin at baseline and at three months, particularly if you have PCOS, are perimenopausal, or have a family history of type 2 diabetes.
5. Use reliable contraception throughout the course and for at least four weeks after stopping.
6. Tell your gynecologist and your primary care provider. Peptide use should be documented in your medical record so that any future adverse event can be attributed and reported.

As of January 2025, the FDA's MedWatch reporting pathway accepts voluntary adverse event reports from patients. If you experience an unexpected effect, filing a report is the only mechanism by which safety signals from unapproved compounded drugs can enter any regulatory database.

The most direct clinical instruction: if a telehealth platform is willing to prescribe CJC-1295 without obtaining a baseline IGF-1, without discussing the pregnancy contraindication explicitly, and without asking about your hormonal status or reproductive life stage, look for a different provider.